While we continue in countdown for launch: Dr.
Post# of 155256
(Total Views: 820)
Posted On: 02/12/2021 7:55:40 AM
While we continue in countdown for launch:
Dr. Patterson has found out that 79% of long haulers with brain-fog (one of the most insidious effects for Long Haulers) have elevated VEGF and he is treating them with Maraviroc.
Why ??
Because RANTES induces pro-angiogenic effects !!!
https://link.springer.com/article/10.1007/s10...e-renderer
Angiogenesis , of course is associated with the grow of malignant tumors and angiogenesis inhibitors constitute a treatment applicable to many types of cancer.
Does it sound familiar ???
Now, in the context of COVID brain fog, it seems that Vyrologix will do the trick with counteracting the effects of VEGF and address the inflammatory-related symptoms in Long Haulers.
In lay terms: Vyrologix can inhibit angiogenesis by interrupting the binding (binding to the receptor) that, according to Dr. Patterson is being directly, or indirectly marked by elevated levels of VEGF. Somewhere or, better, sometime during the (COVID) process the body goes haywire and activated the so called 'angiogenic switch'.
Interesting, and somewhat un-related but of interest as well from the same paper:
However, I here render that Vyrologix will be much more effective that Maraviroc as we know we can go through BBB.
Dr. Patterson has found out that 79% of long haulers with brain-fog (one of the most insidious effects for Long Haulers) have elevated VEGF and he is treating them with Maraviroc.
Why ??
Because RANTES induces pro-angiogenic effects !!!
https://link.springer.com/article/10.1007/s10...e-renderer
Angiogenesis , of course is associated with the grow of malignant tumors and angiogenesis inhibitors constitute a treatment applicable to many types of cancer.
Does it sound familiar ???
Now, in the context of COVID brain fog, it seems that Vyrologix will do the trick with counteracting the effects of VEGF and address the inflammatory-related symptoms in Long Haulers.
Quote:
Moreover, the blockade of RANTES/CCL5 receptors leads to a decrease of neointima formation and macrophage infiltration. Binding of RANTES/CCL5 to GAGs is crucial for its pro-inflammatory activity
In lay terms: Vyrologix can inhibit angiogenesis by interrupting the binding (binding to the receptor) that, according to Dr. Patterson is being directly, or indirectly marked by elevated levels of VEGF. Somewhere or, better, sometime during the (COVID) process the body goes haywire and activated the so called 'angiogenic switch'.
Interesting, and somewhat un-related but of interest as well from the same paper:
Quote:
RANTES/CCL5 has been detected in plasma samples of patients with cardiovascular diseases and is involved in cardiac inflammatory disorders after organ transplantation or arterial injury. The expression of the RANTES/CCL5 receptors, CCR1 and CCR5, on various cell types implicated in atherosclerosis further illustrates their role in this disease
However, I here render that Vyrologix will be much more effective that Maraviroc as we know we can go through BBB.
(20)
(0)